WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Download the WorkBoat Show App! Plan your schedule, explore exhibitors, and access event details anytime. Get the app › Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

73.47 +1.21 (+1.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 686,770
Open 72.97
Bid (Size) 71.00 (1)
Ask (Size) 79.74 (20)
Prev. Close 72.26
Today's Range 72.47 - 74.22
52wk Range 42.01 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Healthcare Stocks We Steer Clear Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory

Performance

YTD
+47.0%
+47.0%
1 Month
-12.8%
-12.8%
3 Month
+6.5%
+6.5%
6 Month
+1.0%
+1.0%
1 Year
+50.0%
+50.0%

More News

Read More
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock
Via Benzinga
Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk
Via Stocktwits
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
Via StockStory
Corcept (CORT) Shares Skyrocket, What You Need To Know
Via StockStory
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 High-Flying Stocks We Approach with Caution
Via StockStory
3 Profitable Stocks That Concern Us
Via StockStory
Why Corcept (CORT) Shares Are Falling Today
Via StockStory
Topics Artificial Intelligence
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
Via StockStory
3 Low-Volatility Stocks We Think Twice About
Via StockStory
Topics Government
Why Corcept (CORT) Stock Is Trading Up Today
Via StockStory
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
Via Benzinga
Topics ETFs
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Via Benzinga
1 Momentum Stock with Competitive Advantages and 2 We Find Risky
Via StockStory
What Analysts Are Saying About Corcept Therapeutics Stock
Via Benzinga
Why Are Corcept (CORT) Shares Soaring Today
Via StockStory
Topics Artificial Intelligence
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 Cash-Producing Stocks That Concern Us
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy
Via Chartmill

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 73.47
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 10/31/25 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 8.52B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.